Disseminated Intravascular Coagulation (DIC)

Categories: Blood diseases, Immune diseases, Skin diseases

Aliases & Classifications for Disseminated Intravascular Coagulation

MalaCards integrated aliases for Disseminated Intravascular Coagulation:

Name: Disseminated Intravascular Coagulation 12 36 29 54 43 15 62 71
Diffuse or Disseminated Intravascular Coagulation 12
Defibrination Syndrome 12
Dic 12


External Ids:

Disease Ontology 12 DOID:11247
KEGG 36 H01587
ICD9CM 34 286.6
MeSH 43 D004211
NCIt 49 C2992
SNOMED-CT 67 67406007
ICD10 32 D65
UMLS 71 C0012739

Summaries for Disseminated Intravascular Coagulation

PubMed Health : 62 About disseminated intravascular coagulation: Disseminated intravascular coagulation (ko-ag-u-LA-shun), or DIC, is a condition in which blood clots form throughout the body's small blood vessels. These blood clots can reduce or block blood flow through the blood vessels, which can damage the body's organs. In DIC, the increased clotting uses up platelets (PLATE-lets) and clotting factors in the blood. Platelets are blood cell fragments that stick together to seal small cuts and breaks on blood vessel walls and stop bleeding. Clotting factors are proteins needed for normal blood clotting. With fewer platelets and clotting factors in the blood, serious bleeding can occur. DIC can cause internal and external bleeding. Internal bleeding occurs inside the body. External bleeding occurs underneath or from the skin or mucosa. (The mucosa is the tissue that lines some organs and body cavities, such as your nose and mouth.) DIC can cause life-threatening bleeding.

MalaCards based summary : Disseminated Intravascular Coagulation, also known as diffuse or disseminated intravascular coagulation, is related to dic in newborn and kidney cortex necrosis. An important gene associated with Disseminated Intravascular Coagulation is SERPINC1 (Serpin Family C Member 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Tranexamic Acid and Anti-inhibitor coagulant complex have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and lung, and related phenotypes are cardiovascular system and homeostasis/metabolism

KEGG : 36 Disseminated intravascular coagulation (DIC) is an acquired syndrome characterised by the intravascular activation of coagulation with loss of localisation arising from different causes. It can originate from and cause damage to the microvasculature, which if sufficiently severe, can produce organ dysfunction. DIC is not a disease entity on itself but is always associated to an underlying disease. The clinical conditions that may be associated with DIC include sepsis, trauma, malignancy, liver disease, obstetric disorders, envenomation, vascular anomalies, and major transfusion reactions. A diagnosis of DIC should be made only in the presence of a clinical condition (causative factor) supported by repeated laboratory tests for coagulation profile and clotting factors. Treatment of DIC is aimed at combating the underlying disorder followed by supportive management.

Wikipedia : 74 Disseminated intravascular coagulation (DIC) is a condition in which blood clots form throughout the... more...

Related Diseases for Disseminated Intravascular Coagulation

Diseases related to Disseminated Intravascular Coagulation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 941)
# Related Disease Score Top Affiliating Genes
1 dic in newborn 33.8 SERPINE1 SERPINC1 F7 F3 F2
2 kidney cortex necrosis 33.3 PLG F2 ADAMTS13
3 protein c deficiency 33.0 THBD SERPINE1 SERPINC1 F9 F5 F2
4 purpura fulminans 33.0 SERPINF2 SERPINC1 F5 F3 F2
5 hellp syndrome 32.6 THBD SERPINE1 SERPINC1 PLAT IL6 F5
6 placental abruption 31.8 THBD SERPINC1 F5 F2
7 toxic shock syndrome 31.8 SERPINC1 IL6 F3
8 acute kidney failure 31.7 PIK3C2A MB F2 ADAMTS13
9 purpura 31.7 THBD SERPINC1 IL6 F3 F2 ADAMTS13
10 eclampsia 31.7 THBD SERPINE1 SERPINC1 F2
11 hemolytic-uremic syndrome 31.6 THBD F3 F2 ADAMTS13
12 meningococcemia 31.5 THBD SERPINE1 SERPINC1 F5
13 aortic aneurysm, familial abdominal, 1 31.4 PLG IL6 ELANE
14 exanthem 31.3 PIK3C2A IL6 F3 F2
15 adult respiratory distress syndrome 31.3 THBD SERPINE1 IL6 F2 ELANE
16 peritonitis 31.3 SERPINE1 IL6 F2 ELANE
17 giant hemangioma 31.3 SERPINC1 F3 F2
18 cardiogenic shock 31.3 PLAT IL6
19 endocarditis 31.2 SERPINE1 SERPINC1 PLAT PIK3C2A IL6 F2
20 pulmonary edema 31.2 SERPINC1 PIK3C2A F2
21 waterhouse-friderichsen syndrome 31.2 SERPINC1 F2
22 heparin-induced thrombocytopenia 31.2 SERPINC1 F3 F10
23 esophageal varix 31.2 SERPINC1 F3 F2
24 infective endocarditis 31.2 SERPINE1 IL6 F2
25 newborn respiratory distress syndrome 31.1 PLG IL6 ELANE
26 acute kidney tubular necrosis 31.0 PIK3C2A MB IL6
27 splenic infarction 31.0 SERPINC1 F3 F2
28 post-cardiac arrest syndrome 30.9 THBD PPIC IL6
29 osteonecrosis 30.9 SERPINE1 SERPINC1 PLG F2
30 leptospirosis 30.9 PIK3C2A IL6 F2
31 respiratory failure 30.9 THBD PIK3C2A IL6 FGA F3 F2
32 hemoglobinuria 30.9 THBD SERPINC1 MB F2
33 severe pre-eclampsia 30.9 SERPINC1 FN1 F5
34 portal hypertension 30.9 SERPINE1 F3 F2 ADAMTS13
35 hemopericardium 30.9 PLG F3 F2
36 nephrosclerosis 30.9 F3 F2 ADAMTS13
37 anuria 30.9 PIK3C2A MB F3 F2 ADAMTS13
38 paroxysmal nocturnal hemoglobinuria 30.9 THBD SERPINC1 F2
39 ischemic colitis 30.8 SERPINE1 SERPINC1 F5 F2
40 dengue hemorrhagic fever 30.8 IL6 F3 F2
41 pericardial effusion 30.8 PIK3C2A IL6 F3 F2
42 blue toe syndrome 30.8 SERPINC1 F3 F2
43 hepatic infarction 30.8 SERPINC1 F3 F2
44 mercury poisoning 30.8 THBD PLAT
45 thrombocytosis 30.8 SERPINC1 IL6 FGA F3 F2
46 hemolytic uremic syndrome, atypical 1 30.8 THBD F3 ADAMTS13
47 aspiration pneumonia 30.7 PIK3C2A IL6 F3 F2
48 bilirubin metabolic disorder 30.7 F9 F3 F2 ADAMTS13
49 hemophilia a 30.7 F9 F7 F3
50 liver cirrhosis 30.7 SERPINF2 SERPINC1 F3 F2 ADAMTS13

Comorbidity relations with Disseminated Intravascular Coagulation via Phenotypic Disease Network (PDN): (show all 14)

Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Aortic Valve Disease 1 Cardiac Arrest
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Mitral Valve Disease Prostate Cancer
Protein-Energy Malnutrition Respiratory Failure

Graphical network of the top 20 diseases related to Disseminated Intravascular Coagulation:

Diseases related to Disseminated Intravascular Coagulation

Symptoms & Phenotypes for Disseminated Intravascular Coagulation

MGI Mouse Phenotypes related to Disseminated Intravascular Coagulation:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 F10 F2 F3 F5 F7 F9
2 homeostasis/metabolism MP:0005376 10.38 ADAMTS13 ELANE F10 F2 F3 F5
3 hematopoietic system MP:0005397 10.31 ADAMTS13 ELANE F2 F3 F9 FGA
4 growth/size/body region MP:0005378 10.23 F2 F3 F5 F7 FN1 IL6
5 immune system MP:0005387 10.21 ADAMTS13 ELANE F2 F3 F9 FGA
6 embryo MP:0005380 10.18 F2 F3 F5 F9 FGA FN1
7 mortality/aging MP:0010768 10.11 ADAMTS13 ELANE F10 F2 F3 F5
8 integument MP:0010771 10.02 F2 F3 F5 FGA FN1 IL6
9 liver/biliary system MP:0005370 9.91 F5 F9 FGA FN1 IL6 PLG
10 reproductive system MP:0005389 9.61 F10 F2 FGA FN1 IL6 PLAT
11 respiratory system MP:0005388 9.23 F2 F3 IL6 MB PLAT PLG

Drugs & Therapeutics for Disseminated Intravascular Coagulation

PubMed Health treatment related to Disseminated Intravascular Coagulation: 62

Treatment for disseminated intravascular coagulation (DIC) depends on its severity and cause. The main goals of treating DIC are to control bleeding and clotting problems and treat the underlying cause.

Drugs for Disseminated Intravascular Coagulation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Tranexamic Acid Approved Phase 4 1197-18-8 5526
Anti-inhibitor coagulant complex Approved, Investigational Phase 4
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
5 Platelet Aggregation Inhibitors Phase 4
6 Liver Extracts Phase 4
7 Prasugrel hydrochloride Phase 4 389574-19-0
8 Antifibrinolytic Agents Phase 4
9 Factor VIII Phase 4
10 Hormones Phase 4
11 Calcium, Dietary Phase 4
12 Analgesics Phase 4
13 Tocolytic Agents Phase 4
14 Anti-Arrhythmia Agents Phase 4
15 Anesthetics Phase 4
16 Anticonvulsants Phase 4
17 calcium channel blockers Phase 4
18 Central Nervous System Depressants Phase 4
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
Icatibant Approved, Investigational Phase 2, Phase 3 130308-48-4, 138614-30-9 71364
Aminocaproic acid Approved, Investigational Phase 2, Phase 3 60-32-2 564
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
Dalteparin Approved Phase 3 9005-49-6
Enoxaparin Approved Phase 3 9005-49-6 772
Cysteine Approved, Nutraceutical Phase 2, Phase 3 52-90-4 5862
Bradykinin Investigational Phase 2, Phase 3 58-82-2 439201
27 Trypsin Inhibitors Phase 2, Phase 3
28 Urinastatin Phase 2, Phase 3
protease inhibitors Phase 3
30 Antithrombins Phase 3
31 HIV Protease Inhibitors Phase 3
32 Serine Proteinase Inhibitors Phase 3
33 Antithrombin III Phase 3
34 Protein Kinase Inhibitors Phase 3
35 Antibiotics, Antitubercular Phase 3
36 Mitogens Phase 3
37 Anti-Bacterial Agents Phase 3
38 Vasodilator Agents Phase 2, Phase 3
39 Hemostatics Phase 2, Phase 3
40 Coagulants Phase 2, Phase 3
41 Immunologic Factors Phase 3
42 Antivenins Phase 3
43 Anti-Inflammatory Agents Phase 2, Phase 3
44 Immunosuppressive Agents Phase 2, Phase 3
45 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
46 Analgesics, Non-Narcotic Phase 2, Phase 3
47 Kininogens Phase 2, Phase 3
48 Antirheumatic Agents Phase 2, Phase 3
49 Bradykinin Receptor Antagonists Phase 2, Phase 3
50 Complement Inactivating Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 A Post-Marketing Clinical Pharmacokinetics Study of ART-123 in DIC Subjects With Renal Impairment Completed NCT01704001 Phase 4 ART-123
2 The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation Completed NCT01099566 Phase 4 Prasugrel;Placebo
3 Whole Blood Clot Stability and Thrombin Generating Capacity Following Treatment With Bypassing Agents (BPA) With and Without and Tranexamic Acid (TXA) in Haemophilia A Patients With inhibitor-an In-vivo Prospective Crossover Study Completed NCT01800435 Phase 4 aPCC, aPCC + TXA;rFVIIa, rFVIIa + TXA
4 Recombinant Human Activated Factor VII as Salvage Therapy in Women With Severe Postpartum Hemorrhage Completed NCT00370877 Phase 4 rFVIIa
5 Effectiveness and Safety of 1g/Hour vs. 2g/Hour of Magnesium Sulfate Maintenance Dose for Eclampsia Prevention: Randomized Clinical Trial Terminated NCT02396030 Phase 4 Magnesium sulfate 50% - 1g/h;Magnesium sulfate 50% - 2g/h
6 The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia Unknown status NCT01865266 Phase 2, Phase 3 Ulinaststin for injection;placebo
7 An Open-label Study of KW-3357 Compared to Plasma-derived Antithrombin for Disseminated Intravascular Coagulation (DIC) Associated With Infection Completed NCT01384903 Phase 3 KW-3357;Plasma-derived antithrombin
8 A Clinical Study of KW-3357 in Patients Diagnosed as Disseminated Intravascular Coagulation (DIC) by the Diagnostic Criteria for DIC Established by the Japanese Ministry of Health and Welfare Completed NCT01384396 Phase 3 KW-3357
9 Randomized Control Trial to Assessed the Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Severe Sepsis Completed NCT02135770 Phase 3 Unfractionated heparin
10 A Phase III, Multi-center, Placebo-Controlled Trial of Sorafenib (BAY43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens for Advanced Disease Completed NCT00863746 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
11 A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy Completed NCT01103323 Phase 3 Regorafenib (Stivarga, BAY73-4506);Placebo
12 SHORTness of Breath In the Emergency Department (SHORTIE) Completed NCT00206830 Phase 2, Phase 3
13 A Comparison of Anavip® and CroFab® in the Treatment of Patients With Crotalinae Envenomation: A Randomized, Prospective, Blinded, Controlled, Comparative, Multicenter Study Completed NCT00636116 Phase 3
14 Calcium for Pre-Eclampsia Prevention (CPEP) Completed NCT00000534 Phase 3 calcium
15 Bradykinin Receptor Antagonism During Cardiopulmonary Bypass Completed NCT00223704 Phase 2, Phase 3 HOE 140;Aminocaproic Acid;Placebo
16 Phase 3 Study of the Efficacy and Safety of Unfractionated Heparin in Patients With Severe Sepsis/Septic Shock With Suspected DIC Recruiting NCT02654561 Phase 3 Heparin Sodium;Saline
17 Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. Not yet recruiting NCT02715492 Phase 3 LMWH
18 A Clinical Study of KW-3357 in Patients Diagnosed as Disseminated Intravascular Coagulation (DIC) by Japanese Association for Acute Medicine-defined DIC Criteria Terminated NCT01384409 Phase 3 KW-3357
19 Does Cleansing of Suction Blood During Cardiac Surgery With Heart and Lung Machine Reduce the Postoperative Inflammatory Response ? Terminated NCT00159926 Phase 3
20 A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects With Sepsis and Disseminated Intravascular Coagulation Completed NCT00487656 Phase 2 ART-123;placebo
21 Ascorbic Acid (Vitamin C) Infusion in Human Sepsis Completed NCT01434121 Phase 1, Phase 2 Ascorbic Acid;Placebo
22 Efficacy and Safety of Factor VIIa (Eptacog Alfa) on Rebleeding After Surgery for Spontaneous Supratentorial Intracerebral Hemorrhage. A Randomized, Controlled, Open-Label, Investigator-Blinded Pilot Study Completed NCT00128050 Phase 2 rFactor VIIa (Eptacog alfa, NovoNordisk);rFVIIa
23 Efficacy and Safety Evaluation of ALT-836 in Patients With Sepsis and Acute Lung Injury/Acute Respiratory Distress Syndrome Completed NCT00879606 Phase 2 ALT-836;Placebo
24 Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest - a Randomized Clinical Trial Recruiting NCT03863015 Phase 2 Tocilizumab 20 Mg/mL Intravenous Solution;isotonic saline
25 Exploratory Efficacy and Safety, Pharmacokinetics and Dose Finding Study of ATryn® (Antithrombin Alfa) in Patients With Disseminated Intravascular Coagulation Associated With Severe Sepsis Terminated NCT00506519 Phase 2 antithrombin alfa (INN name)
26 Incidence and Prognosis of Disseminated Intravscular Coagulation in Patients Severe Sepsis and Septic Shock; Association With 4G/5G Polymorphism of PAI-1 Gene Unknown status NCT01211899
27 Proadrenomedullin as a Severity Score and Prognostic Marker in Intra-abdominal Sepsis Unknown status NCT03061500
28 The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC Receiving Gemcitabine and Cisplatin or Carboplatin Chemotherapy Unknown status NCT02344979
29 Management of Coagulopathy in Cirrhotic Patients Undergoing Invasive Procedures: a Prospective Trial Comparing Standard Management to Thromboelastography Protocol Based Management Unknown status NCT02987712
30 Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of Chronic Philadelphia Negative Myeloproliferative Neoplasms Completed NCT02862366
31 Impaired Platelet Reactivity as an Early Biomarker for Sepsis-related Thrombocytopenia Completed NCT03716310
32 Clinical Evaluation of Novel Biological Markers for the Prediction of Severe Acute Pancreatitis Completed NCT00786591
33 Clinical and Laboratorial Factors Associated With the Severity of Meningococcal Disease Completed NCT01133834
34 Evaluation and Prospective Validation of Clini-biological Parameters Including Initial Hemostasis, Which Improve the Prediction of Death at 1 Month Among Patients Entering Intensive Care Units for Septic Shock Completed NCT01231672
35 TC-325 (HEMOSPRAY™) VS. CURRENT STANDARD OF CARE IN MANAGING MALIGNANT GASTROINTESTINAL BLEEDING: A PILOT STUDY TO INFORM A RANDOMIZED CONTROLLED TRIAL. Completed NCT02135627 TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.
36 Investigating the Association of Shock Index and Hemoglobin Variation With Postpartum Hemorrhage After Vaginal Deliveries: A Prospective Cohort Study Completed NCT03432767
37 A Comparison of B Type Natriuretic Peptide Levels and Hemodynamics Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women - A Pilot Study Completed NCT02527018
38 Coagulation Factor Changes Associated With Postpartum Hysterectomies Completed NCT00456547
39 Comparative Study Between Continuous Epidural Anesthesia Using Standard Epidural Catheter And Continuous Spinal Anesthesia Using Wiley™ Spinal Catheter In Geriatric Patients Undergoing TURP Completed NCT01845389
40 Impact of Using Cumulative SUM (CUSUM) Control Chart in Maternity Department on Mother and Infant Health: a Cluster Randomized Trial Completed NCT01459978
41 International Prospective Registry for the Diagnosis and Management of Disseminated Intravascular Coagulation in the Intensive Care Unit Recruiting NCT03577015
42 Evaluation of Endothelial Dysfunction During Aortic Valvular Replacement by Bioprosthesis With and Without Extracorporeal Circulation Recruiting NCT03135496
43 Waveform Analysis In Snakebite Victims With Hematotoxicity Recruiting NCT03859154
44 Characteristics, Complications and Perinatal Outcomes in Placenta Previa Women: a Prospective, Matched Case-control Study Recruiting NCT03774667
45 Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery Recruiting NCT03064152
46 Effect of Vitamin K in Critically Ill Patients With Spontaneously Increased Pro-thrombin Time Measured With Routine Coagulation Tests and Advanced Coagulation- and Vitamin K-assays Recruiting NCT03782025 Phytomenadione
47 ASSESSment of Peripheral Perfusion, Tissue Oxygen Saturation, Endothelial Function and Coagulation Disorder in Circulatory SHOCK, the ASSESS - SHOCK Study Recruiting NCT03814564
48 Thromboelastometry Guided Disseminated Intravascular Coagulation Prevention After Cesarean Section in Pregnant Women With Placenta Previa Recruiting NCT03266432
49 Hypercoagulation Screening as Innovative Tool for Risk Assessment, Early Diagnosis and Prognosis in Cancer Recruiting NCT02622815
50 International Observational Study on BLood Management for Mechanical Circulatory Support Using Extracorporeal Membrane Oxygenation (OBLEX) Recruiting NCT03714048

Search NIH Clinical Center for Disseminated Intravascular Coagulation

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Antithrombin III, Human

Cochrane evidence based reviews: disseminated intravascular coagulation

Genetic Tests for Disseminated Intravascular Coagulation

Genetic tests related to Disseminated Intravascular Coagulation:

# Genetic test Affiliating Genes
1 Disseminated Intravascular Coagulation 29

Anatomical Context for Disseminated Intravascular Coagulation

MalaCards organs/tissues related to Disseminated Intravascular Coagulation:

Liver, Testes, Lung, Bone, Prostate, Skin, Kidney

Publications for Disseminated Intravascular Coagulation

Articles related to Disseminated Intravascular Coagulation:

(show top 50) (show all 9633)
# Title Authors PMID Year
Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. 54 61
20154285 2010
Heparin-induced thrombocytopenia in two patients undergoing abdominal aortic aneurysm surgery. 54 61
19211578 2010
Acquired factor V inhibitor in a context of sepsis and disseminated intravascular coagulation. 54 61
20052744 2010
[Is venous thrombembolism during pregnancy an indication for routine assay of antithrombin activity and antithrombin supplementation?]. 54 61
20232702 2010
Study of protein C, protein S, and antithrombin III in newborns with sepsis. 54 61
19924026 2010
Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients. 54 61
19487982 2010
Management and outcome of patients with acute traumatic subdural hematomas and pre-injury oral anticoagulation therapy. 54 61
19570326 2009
Recombinant human antithrombin expressed in the milk of non-transgenic goats exhibits high efficiency on rat DIC model. 54 61
19455283 2009
Hemostatic abnormalities in patients with closed head injuries and their role in predicting early mortality. 54 61
19697972 2009
Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness. 54 61
18840625 2009
Relationship between disseminated intravascular coagulation and levels of plasma thrombinogen segment 1+2, D-dimer, and thrombomodulin in patients with multiple injuries. 54 61
19635212 2009
Influence of antithrombin and argatroban on disseminated intravascular coagulation parameters in a patient with septic shock. 54 61
19062078 2009
Non-overt disseminated intravascular coagulation scoring for critically ill patients: the impact of antithrombin levels. 54 61
19350114 2009
[Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin]. 54 61
19189066 2009
Severe liver disease in pregnancy. 54 61
18321514 2008
[Case of severe streptococcus pyogenes pneumonia with streptococcus toxic shock syndrome]. 54 61
18592996 2008
[Early postoperative systemic inflammatory response in patients with lower extremity atherosclerotic gangrene]. 54 61
18652169 2008
Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery. 54 61
18294351 2008
Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. 54 61
18431261 2008
Blood coagulation, inflammation, and malaria. 54 61
18260002 2008
Suppression of HUVEC tissue factor synthesis by antisense oligodeoxynucleotide. 54 61
17920661 2008
Redirection of the reaction between activated protein C and a serpin to the substrate pathway. 54 61
18045665 2008
Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. 54 61
18000608 2007
Update on hemostasis: neurosurgery. 54 61
18019938 2007
Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. 54 61
17944029 2007
4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia. 54 61
17697137 2007
Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study. 54 61
17515857 2007
Enoxaparin-induced skin necrosis: a fatal outcome. 54 61
17667218 2007
Mesenteric venous thrombosis. Associated systemic disorders and hypercoagulability status of 21 surgical patients. 54 61
17629043 2007
Crucial roles of GATA-2 and SP1 in adrenomedullin-affected expression of tissue factor pathway inhibitor in human umbilical vein endothelial cells exposed to lipopolysaccharide. 54 61
17479196 2007
Justifying the clinical use of fresh frozen plasma - an audit. 54 61
17462177 2007
The initial experience of antithrombin III in the management of neonates with necrotizing enterocolitis. 54 61
17448770 2007
[Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation]. 54 61
17563999 2007
Serum albumin levels anticipate antithrombin III activities before and after antithrombin III agent in critical patients with disseminated intravascular coagulation. 54 61
17224787 2007
Antithrombin and hypercoagulability in sepsis: insights from thrombelastography? 54 61
17331267 2007
Recombinant human antithrombin expressed in Chinese hamster ovary cells shows in vivo efficacy on rat DIC model similarly to plasma-derived antithrombin regardless of different N-glycosylation. 54 61
16844203 2007
Double hazard of thrombophilia and bleeding in leukemia. 54 61
18024623 2007
Anti-heparin/PF4 complexes by ELISA in patients with disseminated intravascular coagulation. 54 61
20224256 2007
Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. 54 61
17059423 2007
Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. 54 61
17189219 2006
Haemostatic problems in acute promyelocytic leukaemia. 54 61
16757074 2006
A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. 54 61
16988545 2006
Pathogenesis of thrombocytopenia in cyanotic congenital heart disease. 54 61
16828603 2006
Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital -- meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation. 54 61
16680742 2006
Polymorphism in the tissue factor region is associated with basal but not endotoxin-induced tissue factor-mRNA levels in leukocytes. 54 61
16634740 2006
Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation. 54 61
16708120 2006
Tissue factor in trauma and organ dysfunction. 54 61
16479462 2006
Abdominal cluster transplantation and management of perioperative hemodynamic changes. 54 61
16481278 2006
Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. 54 61
16189276 2006
The Leiden mutation and activated protein C resistance as risk factors for disseminated intravascular coagulation in acutely poisoned patients. 54 61
16496494 2006

Variations for Disseminated Intravascular Coagulation

Expression for Disseminated Intravascular Coagulation

Search GEO for disease gene expression data for Disseminated Intravascular Coagulation.

Pathways for Disseminated Intravascular Coagulation

Pathways related to Disseminated Intravascular Coagulation according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11.98 PLG PLAT IL6 FN1 F2
Show member pathways
Show member pathways
11.87 F9 F7 F2 F10
9 11.85 THBD SERPINE1 IL6 FN1 F3
Show member pathways
11.73 FN1 FGA F2
13 11.49 PLG PLAT FN1 FGA
15 11.22 PLG FN1 F2
16 10.88 F9 F7 F2 F10

GO Terms for Disseminated Intravascular Coagulation

Cellular components related to Disseminated Intravascular Coagulation according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.18 SERPINF2 SERPINE1 SERPINC1 PPIC PLG PLAT
2 extracellular region GO:0005576 10.16 SERPINF2 SERPINE1 SERPINC1 PLG PLAT IL6
3 cell surface GO:0009986 10.03 THBD SERPINF2 PLG PLAT FGA F3
4 blood microparticle GO:0072562 9.88 SERPINF2 SERPINC1 PLG FN1 FGA F2
5 endoplasmic reticulum lumen GO:0005788 9.85 SERPINC1 IL6 FN1 FGA F9 F7
6 platelet alpha granule lumen GO:0031093 9.8 SERPINF2 SERPINE1 PLG FN1 FGA F5
7 Golgi lumen GO:0005796 9.78 F9 F7 F2 F10
8 collagen-containing extracellular matrix GO:0062023 9.73 SERPINF2 SERPINE1 SERPINC1 PLG PLAT FN1
9 fibrinogen complex GO:0005577 9.63 SERPINF2 FN1 FGA
10 extracellular space GO:0005615 9.55 THBD SERPINF2 SERPINE1 SERPINC1 PLG PLAT
11 platelet alpha granule GO:0031091 9.52 FGA F5
12 intrinsic component of external side of plasma membrane GO:0031233 9.51 F3 F10
13 serine-type peptidase complex GO:1905286 9.49 F7 F3

Biological processes related to Disseminated Intravascular Coagulation according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 10.03 PLG PLAT F9 F7 F2 F10
2 post-translational protein modification GO:0043687 9.97 SERPINC1 IL6 FN1 FGA F5
3 leukocyte migration GO:0050900 9.91 THBD FN1 F2 ELANE
4 ER to Golgi vesicle-mediated transport GO:0006888 9.89 F9 F7 F5 F2 F10
5 cellular protein metabolic process GO:0044267 9.87 SERPINC1 PLG IL6 FN1 FGA F5
6 platelet degranulation GO:0002576 9.85 SERPINF2 SERPINE1 PLG FN1 FGA F5
7 cell-matrix adhesion GO:0007160 9.82 FN1 FGA ADAMTS13
8 platelet activation GO:0030168 9.81 IL6 FGA F2 ADAMTS13
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 SERPINF2 IL6 ELANE
10 protein processing GO:0016485 9.77 F7 F3 ADAMTS13
11 acute-phase response GO:0006953 9.76 SERPINF2 IL6 FN1 F2
12 hemostasis GO:0007599 9.7 THBD SERPINC1 PLG FGA F9 F7
13 negative regulation of blood coagulation GO:0030195 9.65 THBD SERPINE1
14 positive regulation of blood coagulation GO:0030194 9.65 SERPINE1 F7 F2
15 negative regulation of fibrinolysis GO:0051918 9.65 THBD SERPINF2 SERPINE1 PLG F2
16 positive regulation of leukocyte chemotaxis GO:0002690 9.64 IL6 F7
17 positive regulation of positive chemotaxis GO:0050927 9.63 F7 F3
18 regulation of blood coagulation GO:0030193 9.63 SERPINC1 F2
19 fibrinolysis GO:0042730 9.63 SERPINF2 SERPINE1 PLG PLAT FGA F2
20 plasminogen activation GO:0031639 9.62 PLAT FGA
21 negative regulation of platelet activation GO:0010544 9.62 THBD F2
22 acute inflammatory response to antigenic stimulus GO:0002438 9.61 SERPINC1 ELANE
23 negative regulation of plasminogen activation GO:0010757 9.58 SERPINF2 SERPINE1
24 interaction with symbiont GO:0051702 9.58 PLG FN1
25 blood coagulation, extrinsic pathway GO:0007598 9.58 F7 F3 F10
26 trans-synaptic signaling by BDNF, modulating synaptic transmission GO:0099183 9.56 PLG PLAT
27 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.55 F7 F3
28 neutrophil mediated killing of gram-negative bacterium GO:0070945 9.54 F2 ELANE
29 negative regulation of chemokine biosynthetic process GO:0045079 9.52 IL6 ELANE
30 blood coagulation GO:0007596 9.4 THBD SERPINC1 PLG PLAT FGA F9

Molecular functions related to Disseminated Intravascular Coagulation according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 THBD SERPINF2 SERPINE1 SERPINC1 PPIC PLG
2 hydrolase activity GO:0016787 10.08 PLG PLAT F9 F7 F2 F10
3 calcium ion binding GO:0005509 9.93 THBD F9 F7 F2 F10 ADAMTS13
4 signaling receptor binding GO:0005102 9.87 SERPINE1 PLG PLAT FN1 FGA F7
5 peptidase activity GO:0008233 9.86 PLG PLAT F9 F7 F2 F10
6 heparin binding GO:0008201 9.73 SERPINC1 FN1 F2 ELANE
7 serine-type endopeptidase inhibitor activity GO:0004867 9.67 SERPINF2 SERPINE1 SERPINC1
8 endopeptidase activity GO:0004175 9.67 PLG F9 F7 ELANE
9 protease binding GO:0002020 9.63 SERPINF2 SERPINE1 SERPINC1 FN1 F3 ELANE
10 serine-type peptidase activity GO:0008236 9.5 PLG PLAT F9 F7 F2 F10
11 serine-type endopeptidase activity GO:0004252 9.23 PLG PLAT F9 F7 F3 F2

Sources for Disseminated Intravascular Coagulation

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....